CRM vs LLY: Which Is the Better Buy?

Side-by-side comparison of Salesforce, Inc. and Eli Lilly and Company โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-26.
Salesforce, Inc. ยท Technology
$236.42
+11.6% upside to fair value
Med Conviction Grade B High Quality
VS
Eli Lilly and Company ยท Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction Grade B High Quality
QuantHub Verdict
CRM has more upside to fair value (+11.6%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric CRM LLY
Current Price $236.42 $1,183.72
Fair Value Estimate $263.88 $1,208.00
Upside to Fair Value +11.6% +2.1%
Market Cap $193.6B $1,114.8B
Forward P/E โ€” โ€”
EV / EBITDA 14.4x 26.8x
Price / Sales 4.4x 14.0x
Price / FCF 12.8x 52.7x
Revenue Growth YoY +10.8% +47.7%
Gross Margin 77.3% 83.4%
Operating Margin 21.4% 49.7%
Return on Equity 20.2% 92.6%
Dividend Yield 0.73% 0.57%
FCF Yield 7.82% 1.9%
Analyst Consensus Buy Strong Buy
Investment Thesis
CRM โ€” Salesforce, Inc.
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4โ€ฆ
LLY โ€” Eli Lilly and Company
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year basโ€ฆ
Accumulation Zones
Metric CRM LLY
Zone Low $197.91 $906.00
Zone High $224.30 $1,026.80
In Buy Zone? No No
โ† CRM Research    LLY Research โ†’    All Research